178 related articles for article (PubMed ID: 19738014)
1. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
Kiser TH; Fish DN; Zamora MR
J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
Vezina HE; Brundage RC; Balfour HH
Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients.
Zhao W; Baudouin V; Zhang D; Deschênes G; Le Guellec C; Jacqz-Aigrain E
Clin Pharmacokinet; 2009; 48(5):321-8. PubMed ID: 19566115
[TBL] [Abstract][Full Text] [Related]
7. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW;
Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
Razonable RR; Paya CV
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
[TBL] [Abstract][Full Text] [Related]
11. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.
Asberg A; Humar A; Rollag H; Jardine AG; Mouas H; Pescovitz MD; Sgarabotto D; Tuncer M; Noronha IL; Hartmann A;
Am J Transplant; 2007 Sep; 7(9):2106-13. PubMed ID: 17640310
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
13. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
14. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N; Csajka C; Pascual M; Manuel O; Lamoth F; Meylan P; Aubert JD; Venetz JP; Soccal P; Decosterd LA; Biollaz J; Buclin T
Antimicrob Agents Chemother; 2009 Jul; 53(7):3017-23. PubMed ID: 19307355
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N; Decosterd LA; Meylan P; Pascual M; Biollaz J; Buclin T
Clin Pharmacokinet; 2009; 48(6):399-418. PubMed ID: 19650679
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.
Jung D; Dorr A
J Clin Pharmacol; 1999 Aug; 39(8):800-4. PubMed ID: 10434231
[TBL] [Abstract][Full Text] [Related]
18. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients.
Asberg A; Humar A; Jardine AG; Rollag H; Pescovitz MD; Mouas H; Bignamini A; Töz H; Dittmer I; Montejo M; Hartmann A;
Am J Transplant; 2009 May; 9(5):1205-13. PubMed ID: 19422345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
